Pharmaceutical

AbbVie acquires Cerevel Therapeutics for $8.7bn

AbbVie has completed its acquisition of all outstanding shares of Cerevel Therapeutics in a deal valued at $8.7bn.

Aug 3, 2024 - 04:00
AbbVie acquires Cerevel Therapeutics for $8.7bn
AbbVie has completed its acquisition of all outstanding shares of Cerevel Therapeutics in a deal valued at $8.7bn.
Read the original article

Tags:

Previous Article

Merck buys Mirus Bio to boost viral vector bioprocessing capacity

Next Article

AAIC 2024: Eisai presents positive long-term data with Leqembi

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Simtra BioPharma to invest more than $250m in US facility

Simtra BioPharma to invest more than $250m in US facility

Mar 1, 2024

IGC Pharma signs agreement to adopt AI solutions into drug discovery

IGC Pharma signs agreement to adopt AI solutions into d...

Nov 22, 2023

M&A in pharmaceutical in Australia remained flat in Q2 ...

Jul 27, 2023